Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COMMENTARY
Pharmacies Reel from Pricey Drug Waste, Sparking Calls for Packaging Overhaul and Price Penalties
Leftover stocks of high-priced medicines are emerging as a serious headache for Japanese pharmacies, fueling financial stress and even bankruptcies in some cases. The Japan Pharmaceutical Association (JPA) is urging drug makers to adjust their sales packaging units to match…
To read the full story
Related Article
- Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
July 11, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
COMMENTARY
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
- A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
- Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
- Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…